文献速递乳腺癌

恩贝妥单抗联合HB1801新辅助治疗ERBB2阳性乳腺癌的3期随机临床试验

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-09-03

这项多中心3期注册随机试验纳入521例II-III期ERBB2阳性乳腺癌患者,比较恩贝妥单抗(ERBB2双旁位抗体)联合HB1801(无溶剂白蛋白结合型多西他赛)方案与曲妥珠单抗+帕妥珠单抗+多西他赛标准方案。

要点

  • 试验组tpCR率62.4%,较对照组51.2%提高11.4个百分点,差异有统计学意义
  • 各亚组获益一致,包括激素受体阳性/阴性、早期/局部晚期及是否联合卡铂
  • 3-4级治疗相关不良事件发生率两组相近,安全性可控

核心结论

  • 恩贝妥单抗联合HB1801新辅助治疗较标准方案显著提高ERBB2阳性早期乳腺癌的tpCR率,且安全性高度可控。

主要发现

  • 亚组获益一致:激素受体阳性51.7% vs 44.4%,激素受体阴性76.3% vs 59.5%,早期63.8% vs 51.8%,局部晚期59.6% vs 50.0%,联合卡铂66.7% vs 54.5%,未联合卡铂59.2% vs 48.6%。
  • 3-4级治疗相关不良事件试验组29.3%(77例)、对照组28.3%(73例),无治疗相关死亡。

关键数值与推荐

  • 主要终点为盲法独立评审委员会评估的tpCR;试验组与对照组分别接受6周期新辅助治疗,方案含或不含卡铂。

临床怎么用

  • 该联合方案可能为ERBB2阳性早期乳腺癌新辅助治疗提供新的选择,但需长期生存随访进一步验证。

局限性

  • 原文指出仍需长期生存随访分析;摘要未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The combination of neoadjuvant taxanes with trastuzumab and pertuzumab remains the cornerstone treatment strategy in ERBB2-positive breast cancer. Anbenitamab (a ERBB2-biparatopic antibody that induces profound receptor clustering) and HB1801 (a solvent-free albumin-bound docetaxel), have shown promising antitumor activity and an acceptable safety profile in patients with breast cancer. OBJECTIVE: To evaluate whether neoadjuvant anbenitamab combined with HB1801 could improve efficacy without increasing toxic effects for patients with early ERBB2-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 3 registrational randomized clinical trial enrolled patients with stage II or III ERBB2-positive breast cancer from 61 hospitals in China between December 19, 2024, and August 29, 2025 (data cutoff: January 28, 2026). Data were analyzed from February 1 to March 20, 2026. INTERVENTIONS: Patients were randomly assigned (1:1) to receive 6 cycles of neoadjuvant anbenitamab plus HB1801, with or without carboplatin (investigational group), or trastuzumab, pertuzumab, and docetaxel, with or without carboplatin (control group). MAIN OUTCOMES AND MEASURES: The primary end point was total pathological complete response (tpCR) assessed by a blinded independent review committee. RESULTS: Among 521 included patients (median [IQR] age, 52.0 [23-79] years), 263 were randomized to the investigational group and 258 to the control group. The tpCR rate was significantly higher in the investigational group than the control group (164 patients [62.4%] vs 132 patients [51.2%]; absolute difference, 11.4 [95% CI, 3.2 to 19.6] percentage points; P = .004). Benefit was consistent across subgroups, including subgroups with hormone receptor-positive disease (77 patients [51.7%] vs 63 patients [44.4%]), hormone receptor-negative disease (87 patients [76.3%] vs 69 patients [59.5%]), early-stage disease (111 patients [63.8%] vs 87 patients [51.8%]), locally advanced disease (53 patients [59.6%] vs 45 patients [50.0%]), with carboplatin treatment (74 patients [66.7%] vs 61 patients [54.5%]), and without carboplatin treatment (90 patients [59.2%] vs 71 patients [48.6%]). Grade 3 or 4 treatment-related adverse events occurred in 77 patients (29.3%) in the investigational group and 73 patients (28.3%) of the control group. No treatment-related deaths occurred. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that neoadjuvant anbenitamab and HB1801 in patients with breast cancer significantly improved the tpCR rate compared with standard therapy with a highly manageable safety profile. This new combination may offer an improved treatment option, although long-term survival follow-up analyses are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06747338.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li J, Liu T, Yu KD, et al. Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42690668. doi:10.1001/jamaoncol.2026.3329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。